JP2015519347A5 - - Google Patents

Info

Publication number

JP2015519347A5

JP2015519347A5 JP2015514191A JP2015514191A JP2015519347A5 JP 2015519347 A5 JP2015519347 A5 JP 2015519347A5 JP 2015514191 A JP2015514191 A JP 2015514191A JP 2015514191 A JP2015514191 A JP 2015514191A JP 2015519347 A5 JP2015519347 A5 JP 2015519347A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

composition according

receptor

disorder

disease

Prior art date

2013-05-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
• 229930003827 cannabinoid Natural products 0.000 claims description 30
• 239000003557 cannabinoid Substances 0.000 claims description 30
• 150000001875 compounds Chemical class 0.000 claims description 27
• 102000005962 receptors Human genes 0.000 claims description 27
• 108020003175 receptors Proteins 0.000 claims description 27
• 201000010099 disease Diseases 0.000 claims description 18
• 208000035475 disorder Diseases 0.000 claims description 18
• 230000000694 effects Effects 0.000 claims description 18
• 206010028980 Neoplasm Diseases 0.000 claims description 9
• 229910052739 hydrogen Inorganic materials 0.000 claims description 8
• 239000001257 hydrogen Substances 0.000 claims description 8
• 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
• 125000000217 alkyl group Chemical group 0.000 claims description 6
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
• 208000024891 symptom Diseases 0.000 claims description 5
• 125000002252 acyl group Chemical group 0.000 claims description 4
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
• 230000010261 cell growth Effects 0.000 claims description 4
• 239000003814 drug Substances 0.000 claims description 4
• 229940124597 therapeutic agent Drugs 0.000 claims description 4
• 201000011510 cancer Diseases 0.000 claims description 3
• 206010003571 Astrocytoma Diseases 0.000 claims description 2
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
• 206010009944 Colon cancer Diseases 0.000 claims description 2
• 102100033061 G-protein coupled receptor 55 Human genes 0.000 claims description 2
• 101000871151 Homo sapiens G-protein coupled receptor 55 Proteins 0.000 claims description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
• -1 aminocarbonyl (carbamoyl) Chemical group 0.000 claims description 2
• 239000002246 antineoplastic agent Substances 0.000 claims description 2
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
• 208000029742 colonic neoplasm Diseases 0.000 claims description 2
• 229940127089 cytotoxic agent Drugs 0.000 claims description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
• 208000005017 glioblastoma Diseases 0.000 claims description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
• 201000005202 lung cancer Diseases 0.000 claims description 2
• 208000020816 lung neoplasm Diseases 0.000 claims description 2
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
• 208000030266 primary brain neoplasm Diseases 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 23
• 206010006187 Breast cancer Diseases 0.000 claims 1
• 208000026310 Breast neoplasm Diseases 0.000 claims 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
• 201000007270 liver cancer Diseases 0.000 claims 1
• 208000014018 liver neoplasm Diseases 0.000 claims 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
• 201000002528 pancreatic cancer Diseases 0.000 claims 1
• 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
• 238000000034 method Methods 0.000 description 20
• 239000000126 substance Substances 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 2
• GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
• 229940125797 compound 12 Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1